Merck & Co., Inc. and Pfizer Enter Worldwide Collaboration Agreement to Develop and Commercialize Ertugliflozin, an Investigational Medicine for Type 2 Diabetes

Dateline City: 

WHITEHOUSE STATION, N.J. & NEW YORK

WHITEHOUSE STATION, N.J. & NEW YORK--(BUSINESS WIRE)--Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States
and Canada (“Merck”), and Pfizer Inc. (NYSE:PFE) today announced that
they have entered into a worldwide (except Japan) collaboration
agreement for the development and commercialization of Pfizer’s
ertugliflozin (PF-04971729), an investigational oral sodium glucose
cotransporter (SGLT2) inhibitor being evaluated for the treatment of
type 2 diabetes.
Language: 

English

Contact HTML: 

Merck Media Relations:Steven Cragle: [phone]Kim Hamilton: [phone]orPfizer Media Relations:Joan Campion: [phone]orMerck Investor Relations:Carol Ferguson: [phone]Justin Holko: [phone]orPfizer Investor Relations:Chuck Triano: [phone]

Ticker Slug: 

Ticker: MRK Exchange: NYSE

Ticker: PFE Exchange: NYSE

read more

Source: Merck.com - Research and Development News - April 29, 2013 Category: Pharmaceuticals Authors: hq_site_admin Tags: Research and Development News Corporate News Source Type: news